3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
99
Myelodysplastic Syndromes
56
Leukemia, Myelomonocytic, Chronic
23
Leukemia
17
Recurrence
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, Non-Hodgkin
10
Hematologic Neoplasms
9
Multiple Myeloma
8
Hodgkin Disease
8
Neoplasms
6
Myeloproliferative Disorders
6
Leukemia, Myeloid
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Carcinoma, Non-Small-Cell Lung
6
Myelodysplastic-Myeloproliferative Diseases
5
Lymphoma
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Sarcoma
4
Primary Myelofibrosis
4
Ovarian Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Leukemia, Biphenotypic, Acute
4
Head and Neck Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Melanoma
3
Lymphoma, T-Cell, Peripheral
3
Interventions
ripretinib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
avapritinib
1
auricularum
1
Ranitidine
1
Ibuprofen
1
Diphenhydramine
1
Dexamethasone
1
Calcium Dobesilate
1
Azacitidine
1
Acetaminophen
1
AK002
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Mastocytosis, Systemic
×
Azacitidine
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled